Insider buying last 90 days
No open-market insider purchases were filed for AZN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AZN insider filing, plotted on the chart in Gekko.Open AZN in Gekko
NYSE: AZN
AstraZeneca (AZN) Stock Analysis & Forecast
$166.08−0.06 (0.0%)
Close on Sep 18, 2026. Page updated Sep 19, 9:14 pm ET.
Gekko Brief
AI summaryAZN closes at $166.08, sitting between its 50-day average of $164.27 and 200-day average of $182.64. The GekkoIndex reads 54.2, placing the stock in the Neutral zone, down 8 over the past five readings. Against Gekko Fair Value of $281.29, the stock trades 41% below that level. Over the past month the shares are up 0.7%, though three-month and six-month returns stand at -5.1% and -12.1%, while the one-year return is 12.7%.
News this week centers on regulatory and pipeline developments alongside analyst commentary. The FDA granted priority review to AZN's filing for efzimfotase alfa in rare bone disease, and the AstraZeneca-Daiichi Sankyo breast cancer treatment Enhertu was cleared for NHS use in England, having been available in Scotland since 2023. J.P. Morgan reiterated an Overweight rating, pointing to six Phase III readouts expected in 2027 with over $10 billion in potential peak sales, while other coverage weighed the company's broad late-stage pipeline against recent setbacks, noting 20-plus expected readouts ahead. An insider, Michel Demare, bought 2,500 shares on 14 September at an average price of £121.21, a transaction worth £303,025, within the last 90 days.
Looking ahead, AZN's next earnings date falls on 30 October, 40 days out and beyond a typical 20-trading-day hold. The prior quarter, reported 27 July, showed EPS of $2.63 against an estimate of $2.50, with a 1.9% reaction, and the company has beaten estimates in 7 of the last 8 quarters. One billionaire holder is recorded. Seasonally, the next 20 trading days have averaged -1.1% over 5 years, rising in 3 of them. The consensus analyst target stands at $212.17, implying 27.8% upside.
Written by AI and checked automatically against the figures on this page. Generated Sep 20, 2026 from the data above.
Price vs fair value
Close $166.08200-day averageGekko Fair Value $281.29
Key stats
- Market cap
- $257.6B
- P/E ratio
- 24.4
- Forward P/E
- 14.2
- EPS, TTM
- $6.81
- Revenue, TTM
- $61.37B
- Profit margin
- 17%
- Dividend yield
- 1.98%
- Beta
- 0.21
- Volume
- 3.06M avg 3.11M
- 1-year return
- +12.7%
- Typical daily move
- ±2%
- Typical 20-day move
- ±4.9%
- 50-day average
- $164.27
- 200-day average
- $182.64
- Next earnings
- Oct 30 before open
- Shares outstanding
- 1.55B
AstraZeneca swing-trade checklist
AstraZeneca scores 2 supportive, 3 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive3 mixed0 headwinds
- Trendmixed
Averages disagree
Close $166.08 sits between the 50-day ($164.27) and 200-day ($182.64) averages, or the averages disagree.
See the chart - GekkoIndexmixed
54.2, Neutral
Reading 54.2 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
41.0% below
Price is 41% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 40 days
Next report Oct 30, 2026, 40 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
−1.1% on average
From this point in the calendar, the next 20 trading days averaged −1.1% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
AstraZeneca stock chart and price history
AstraZeneca closed at $166.08 on Sep 18, 2026, +12.7% over the past year, inside a 52-week range of $141.80 to $212.71.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +0.7%
- 3 months
- −5.1%
- 6 months
- −12.1%
- 1 year
- +12.7%
The full AZN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AZN in Gekko
Follow AstraZeneca through every session
Put AZN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AZN in GekkoFree for 7 days. No credit card required.
About AstraZeneca
AstraZeneca is a biopharmaceutical company that takes medicines from early-stage research all the way to manufacturing and sale. Its drug lineup covers heart, kidney and metabolic disorders as well as cancer treatment, featuring names such as Tagrisso, Farxiga and Symbicort. The company also supplies products tied to COVID-19 and to rare medical conditions, among them Vaxzevria and Soliris.
Sales reach both general practitioners and specialists, carried out through teams of representatives and local offices spread across Britain, mainland Europe, the Americas, Asia, Africa and Australasia. Beyond its own labs, AstraZeneca teams up with outside groups on new science, working alongside Neurimmune on an antibody treatment, BenevolentAI on lupus research, Lunit on AI tools for reading lung cancer scans, and Absci on machine-learning methods for spotting oncology drug targets.
The business dates back to 1992, when it was formed as Zeneca Group PLC, before adopting the AstraZeneca name in April 1999. It runs its operations from Cambridge in the United Kingdom, and its stock trades on the NYSE under the ticker AZN.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- astrazeneca.com
AstraZeneca GekkoIndex: the smart money zone
AstraZeneca’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 54.2, in the Neutral zone, down 8 points over five sessions.
54.2Neutral
Down 8 points over five sessions, from the Accumulation zone.
Reading for Sep 18, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | +1.3% | +3.2% | ||
| Accumulation | 157 | +0.6% | +0.6% | ||
| Neutral (current zone) | 332 | +0.1% | +1.3% | ||
| Distribution | 11 | −1.3% | +2.2% | ||
| Selling | 2 | Too few readings yet | |||
Average AZN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the AZN price, zone by zone.Track AZN in Gekko
Is AstraZeneca stock overvalued? Gekko Fair Value
AstraZeneca trades 41.0% below Gekko Fair Value of $281.29, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what AstraZeneca shares are worth, recalculated every trading day.
$281.29
Gekko Fair Value, Sep 19, 2026
41.0% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open AZN in Gekko
AstraZeneca insider and Congress trading
No open-market insider purchases were filed for AstraZeneca, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AZN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AZN, plotted on the chart in Gekko.Open AZN in Gekko
Buybacks
AstraZeneca has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $46.33M
- As a share of market cap
- 0.02%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds AZN.
0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
AstraZeneca earnings: next date and track record
AstraZeneca reports on Oct 30, 2026, before the open (40 days away), and beat the EPS estimate in 7 of its last 8 reports.
Next earnings report
Oct 30, 2026
Expected before the open, 40 days away
- EPS estimate
- $2.62
- Revenue estimate
- $16.06B
7 of 8reports beat the EPS estimate
±3%average move across the report
7 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Jul 27, 2026 AI summary
- What they said
- AstraZeneca reported H1 2026 total revenue growth of 6% (11% excluding LOE-impacted Farxiga and Brilinta), with core EPS up 11%. Oncology and Rare Disease delivered strong double-digit growth. Six Phase III programs produced positive results, with 30 major market approvals secured including 2 NMEs (Etcamah for breast cancer, Baxfendy for hypertension). China growth was pressured by volume-based procurement. CARDIO-TTRansform trial results were disappointing.
- Guidance
- Management reaffirmed confidence in the $80 billion 2030 revenue target, noting it is risk-adjusted and built on portfolio diversification rather than single programs. NRDL additions and new China approvals are expected to drive future growth in that market.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Jul 27, 2026 | $2.63 est $2.50 | $15.38B est $15.44B | +1.9% |
| Apr 29, 2026 | $1.29 est $1.27 | $15.29B est $14.93B | +0.4% |
| Nov 6, 2025 | $2.38 est $2.29 | $15.19B est $15.42B | +0.6% |
| Sep 30, 2025 | $1.19 est $1.13 | $15.19B est $15.42B | +9.1% |
| Jul 29, 2025 | $2.18 est $2.16 | $14.46B est $14.76B | +6.0% |
| Jun 30, 2025 | $1.09 est $1.46 | $14.46B est $14.76B | +1.1% |
| Apr 29, 2025 | $2.48 est $2.25 | $13.59B est $14.06B | +5.0% |
| Mar 31, 2025 | $1.25 est $1.12 | $13.59B est $14.06B | −0.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
AstraZeneca stock forecast and analyst price targets
Analysts’ average 12-month price target for AstraZeneca is $212.17, +27.8% from the last close.
$212.17consensus 12-month target, +27.8% from the last close
+1.3%average 20-day move after past Neutral readings
−1.1%average move over the next 20 trading days in the last 5 years
±2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
AstraZeneca seasonality: the next 20 trading days
Over the next 20 trading days from Sep 19, AstraZeneca averaged −1.1% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.1% | 3 of 5 |
| Next 10 trading days | +3.5% | 4 of 5 |
| Next 15 trading days | +1.2% | 3 of 5 |
| Next 20 trading days | −1.1% | 3 of 5 |
| Next 30 trading days | +2.5% | 3 of 5 |
For scale, AZN’s typical 20-trading-day move in either direction is about 4.9%.
AstraZeneca market cap and key statistics
AstraZeneca’s market cap is $257.6B, with a P/E ratio of 24.4 and revenue of $61.37B over the last twelve months.
Valuation
- Market cap
- $257.6B
- P/E ratio
- 24.4
- Forward P/E
- 14.2
- EPS, TTM
- $6.81
- Gekko Fair Value
- $281.29
Trading
- Volume
- 3.06M
- Avg volume, 20 days
- 3.11M
- 52-week high
- $212.71
- 52-week low
- $141.80
- Shares outstanding
- 1.55B
Financials
- Revenue, TTM
- $61.37B
- Profit margin
- 17%
- Return on equity
- 22%
- Quarterly earnings growth, YoY
- +2.5%
Risk and income
- Beta
- 0.21
- Typical daily move
- ±2%
- Typical 20-day move
- ±4.9%
- Dividend yield
- 1.98%
AstraZeneca stock news this week
Coverage of AstraZeneca this week reads positive: 2 positive, 2 neutral and 1 negative headlines.
- FDA Grants Priority Review to AZN's Filing for Rare Bone Disease DrugZacks Investment Research, Sep 18
- Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?Zacks Investment Research, Sep 18
- AstraZeneca-Daiichi breast cancer drug cleared for NHS use in EnglandReuters, Sep 17
- AstraZeneca Shares Rise as J.P. Morgan Stays OverweightYahoo Finance, Sep 16
- Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?Zacks Investment Research, Sep 16
- AstraZeneca (LON:AZN) Insider Michel Demare Buys 2,500 Shares of StockDefense World, Sep 16
AstraZeneca peers
AstraZeneca’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Accumulation | 15.7% above |
| JNJJohnson & Johnson | Neutral | 2.7% below |
| ABBVAbbVie | Neutral | 22.6% above |
| MRKMerck | Neutral | 7.3% below |
| PFEPfizer | Neutral | 9.8% below |
| VRTXVertex Pharmaceuticals | Accumulation | 9.7% above |
A peer links to its own page where one exists.
AstraZeneca stock FAQ
What is AstraZeneca’s market cap?
AstraZeneca’s market cap is $257.6B at the Sep 18, 2026 close of $166.08, with 1.55B shares outstanding. The shares trade on a P/E ratio of 24.4.
What is the AstraZeneca stock forecast?
The consensus analyst 12-month price target for AstraZeneca is $212.17, +27.8% from the last close. Gekko doesn’t publish price predictions of its own.
Is AstraZeneca stock overvalued or undervalued?
On Gekko’s estimate AstraZeneca is undervalued: the Sep 18, 2026 close of $166.08 is 41.0% below Gekko Fair Value of $281.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does AstraZeneca report earnings next?
AstraZeneca is expected to report on Oct 30, 2026, before the market opens (40 days away). Analysts expect earnings of $2.62 per share on revenue of $16.06B. AstraZeneca beat the earnings estimate in 7 of its last 8 reports, moving 3% on average across the report.
What is AstraZeneca’s 52-week high and low?
AstraZeneca’s 52-week high is $212.71 and its 52-week low is $141.80; it closed at $166.08 on Sep 18, 2026, +12.7% over the past year.
Is AstraZeneca stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and earnings risk), 3 as mixed (trend, gekkoindex and seasonality). The checklist is a description of current data, not a recommendation.
How this page works
Prices and signals update after every US market close; the GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See AstraZeneca the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,349 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.